Dallas Diabetes Research Center
Dallas, Texas 75230-6885
0 studies enrolling now · 32 studies all time
What they study most
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Cardiomyopathies, Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias, NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Obesity, Overweight
Studies at this site
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes — Completed
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
- A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes — Running, not enrolling
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities — Completed
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) — Completed
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight — Completed
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy — Completed
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin — Completed
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time — Completed
- Safety and Efficacy Study of S-309309 in Obese Adults — Completed
- A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
- A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 — Completed
- Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus — Completed
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss — Completed
- A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program — Completed
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight — Completed
- A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin — Completed
- A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus — Completed
- A Study of LY3437943 in Participants Who Have Obesity or Are Overweight — Completed
- A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities — Completed
- A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
- Evaluation of TTP399 in Patients With Type 1 Diabetes — Completed
- Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus — Completed
- A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) — Completed
- A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY — Completed
- Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy — Running, not enrolling
- A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
- A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) — Completed
- A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus — Completed
- A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes — Completed
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis — Completed
- A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants — Completed